Piper Sandler analyst Allison Bratzel reiterated a Buy rating on IO Biotech (IOBT – Research Report) today and set a price target of $10.00.

IO Biotech has a 52-week low of $0.66 and a 52-week high of $1.85. Institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in shares of IO ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

IO Biotech (NASDAQ:IOBT – Get Free Report) is projected to release its earnings data on Tuesday, March 4th. Analysts expect IO Biotech to post earnings of ($0.39) per share for the quarter.

IO Biotech’s proprietary T-win® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within the ...

The full IO Biotech team is proud to be leading the next frontier of immune-oncology with the development of therapeutic cancer vaccines for these and other difficult-to-treat cancers. Our ...

IO Biotech's proprietary T-win ® platform is designed to selectively modulate TGF-β activity rather than fully inhibit it, targeting both tumor cells and key immune-suppressive cells within the TME.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...